The PI3Kα Inhibitor Alpelisib Has Activity in PIK3CA-altered Tumors
- PMID: 29453241
- DOI: 10.1158/2159-8290.CD-RW2018-027
The PI3Kα Inhibitor Alpelisib Has Activity in PIK3CA-altered Tumors
Abstract
The PI3Kα inhibitor alpelisib achieved a 58.2% disease control rate in PIK3CA-altered solid tumors.
©2018 American Association for Cancer Research.
Comment on
-
Phosphatidylinositol 3-Kinase α-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study.J Clin Oncol. 2018 May 1;36(13):1291-1299. doi: 10.1200/JCO.2017.72.7107. Epub 2018 Feb 5. J Clin Oncol. 2018. PMID: 29401002 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
